Jasper Therapeutics (JSPR) Enterprise Value (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Enterprise Value of -$28.7 million for Q4 2025, up 59.95% year-over-year from -$17.9 million in Q4 2024, and up 43.63% quarter-over-quarter from -$50.9 million in Q3 2025.
Jasper Therapeutics (JSPR) Enterprise Value (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$28.7 million for Q4 2025.
- In Q4 2025, Enterprise Value rose 59.95% year-over-year to -$28.7 million; the TTM figure through Dec 2025 stood at -$28.7 million (up 59.95% YoY), while the FY2025 annual figure was -$28.7 million, up 59.95% from the prior year.
- Enterprise Value for Q4 2025 stood at -$28.7 million, up from -$50.9 million in the prior quarter.
- The five-year high for Enterprise Value was -$309730.0 in Q2 2021, with the low at -$129.4 million in Q1 2023.
- The 5-year median for Enterprise Value is -$70.5 million (2022), against an average of -$69.8 million.
- The sharpest annual moves came in 2021 and 2022: Enterprise Value jumped 66.12% in 2021, then tumbled 19534.52% in 2022.
- Jasper Therapeutics' Enterprise Value stood at -$84.7 million in 2021, then jumped by 54.84% to -$38.2 million in 2022, then tumbled by 127.16% to -$86.9 million in 2023, then increased by 17.55% to -$71.6 million in 2024, then soared by 59.95% to -$28.7 million in 2025.
- Business Quant data shows JSPR's Enterprise Value at -$28.7 million in Q4 2025, -$50.9 million in Q3 2025, and -$39.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | -7.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -28.69 Mn |
| Sep 30, 2025 | -50.90 Mn |
| Jun 30, 2025 | -39.50 Mn |
| Mar 31, 2025 | -48.80 Mn |
| Dec 31, 2024 | -71.64 Mn |
| Sep 30, 2024 | -92.50 Mn |
| Jun 30, 2024 | -106.82 Mn |
| Mar 31, 2024 | -118.48 Mn |
| Dec 31, 2023 | -86.89 Mn |
| Sep 30, 2023 | -102.87 Mn |
| Jun 30, 2023 | -115.81 Mn |
| Mar 31, 2023 | -129.40 Mn |
| Dec 31, 2022 | -38.25 Mn |
| Sep 30, 2022 | -49.95 Mn |
| Jun 30, 2022 | -60.81 Mn |
| Mar 31, 2022 | -69.40 Mn |
| Dec 31, 2021 | -84.70 Mn |
| Sep 30, 2021 | -99.91 Mn |
| Jun 30, 2021 | -309,730.00 |
| Mar 31, 2021 | -590,605.00 |